Aligos Therapeutics, Inc. (ALGS) › Operating IncomeAligos Therapeutics, Inc. (ALGS) — Operating IncomeAnnual figures by fiscal year, from SEC filings.2019: -$54.04M2020: -$97.83M2021: -$128.32M2022: -$97.58M2023: -$88.13M2024: -$89.15M2025: -$87.98M-$87.98M2019Operating Income (USD)2025Fiscal YearOperating IncomeChange YoY2025-$87.98M+1.3%2024-$89.15M-1.2%2023-$88.13M+9.7%2022-$97.58M+24.0%2021-$128.32M-31.2%2020-$97.83M-81.0%2019-$54.04M—Other metrics: RevenueCost of RevenueGross ProfitNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per Share